Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Muhammad Wasif Saif

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8154-957X; OpenAlex author ID A5055424340, A5110323346. Sources: OpenAlex.

Their work

Papers
165 (first author 46, last author 83)
Trials
0
Grants
0
Labs led
5
Collaborators
182
Papers, trials and grants by year

2011: 25 papers · 2012: 25 papers · 2013: 29 papers · 2014: 36 papers · 2015: 4 papers · 2016: 9 papers · 2017: 6 papers · 2018: 2 papers · 2019: 6 papers · 2020: 9 papers · 2021: 6 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 50 of 165

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Ranking targeted therapies in advanced pancreatic adenocarcinoma: insights from a network meta-analysis. Co-author DOI 10.21037/jgo-2026-0209↗
  3. Pancreatic ductal adenocarcinoma and edema: reassessing cachexia markers. Last author DOI 10.21037/jgo-2026-0216↗
  4. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  5. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  6. TGFB2 Expression and Methylation Predict Overall Survival in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26136357↗
  7. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  8. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  9. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Last author DOI 10.1177/17562848211014818↗
  10. Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? Last author DOI 10.33696/signaling.2.037↗
  11. The Role of Olaparib in Metastatic Pancreatic Cancer. Last author PMID 34151318↗
  12. Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer. Co-author PMID 34354555↗
  13. New Potential Options for SBRT in Pancreatic Cancer. Last author PMID 34355218↗
  14. From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review. Co-author PMID 34483790↗
  15. Increasing access to multidisciplinary care in pancreatic cancer. Co-author DOI 10.1002/pon.5493↗
  16. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Co-author DOI 10.1016/s2468-1253(19)30327-9↗
  17. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Last author DOI 10.1177/1756284820974912↗
  18. Delicate Balance Between Quality and Quantity of Life: Palliative Chemotherapy for Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1200/op.20.00340↗
  19. Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn. Co-author DOI 10.17140/poj-4-e012↗
  20. Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat? First author PMID 32377176↗
  21. New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. Co-author PMID 32905526↗
  22. Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surger… Co-author PMID 32982620↗
  23. Years of Fight against Pancreatic Cancer by RGB: Lessons to be Learnt. Last author PMID 33634269↗
  24. Capecitabine for the treatment of pancreatic cancer. Last author DOI 10.1080/14656566.2018.1560422↗
  25. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Last author DOI 10.1080/17425255.2019.1637417↗
  26. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… First author DOI 10.1089/pancan.2019.0012↗
  27. The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Last author DOI 10.17140/poj-3-110↗
  28. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Last author DOI 10.17140/poj-3-e010↗
  29. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session. Last author DOI 10.17140/poj-3-e011↗
  30. Masitinib in treatment of pancreatic cancer. Last author DOI 10.1080/14656566.2018.1459566↗
  31. Screening of Pancreatic Cancer. Co-author PMID 30057517↗
  32. Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine? Last author DOI 10.1007/s00280-017-3374-x↗
  33. Second line treatment options for pancreatic cancer. First author DOI 10.1080/14656566.2017.1369955↗
  34. T cell optimization for the treatment of pancreatic cancer. First author DOI 10.1080/14712598.2017.1369948↗
  35. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. First author DOI 10.1080/14728214.2017.1362388↗
  36. Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Last author DOI 10.1177/1756283x17705328↗
  37. Stauffer's Syndrome in Pancreatic Cancer: First Case Report. First author DOI 10.7759/cureus.1230↗
  38. Metformin and pancreatic cancer: Is there a role? Last author DOI 10.1007/s00280-015-2948-8↗
  39. Immunotherapy for pancreatic cancer. First author DOI 10.1007/s00432-016-2119-2↗
  40. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Last author DOI 10.1080/14737140.2016.1192471↗
  41. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Last author DOI 10.1177/1756283x15622601↗
  42. A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Last author DOI 10.1177/1756283x15622779↗
  43. Neoadjuvant therapy for pancreatic cancer: an ongoing debate. First author DOI 10.1177/1756283x16646524↗
  44. Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. Last author DOI 10.7759/cureus.687↗
  45. Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. Co-author DOI 10.7759/cureus.689↗
  46. Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. Last author PMID 29568247↗
  47. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Last author DOI 10.1097/cad.0000000000000178↗
  48. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? First author DOI 10.4251/wjgo.v7.i10.172↗
  49. Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). First author DOI 10.6092/1590-8577/2955↗
  50. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. Last author PMID 26637914↗

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 5 shared papers, 2024–2026 · strength 1.22
  2. Konstantinos Nikolaos Syrigos · 17 shared papers, 2011–2016 · strength 1.04
  3. Philip A. Philip · 5 shared papers, 2019–2026 · strength 1.02
  4. Kostas Syrigos · 18 shared papers, 2011–2016 · strength 0.97
  5. Sahar F. Bannoura · 4 shared papers, 2024–2026 · strength 0.72
  6. Md. Hafiz Uddin · 4 shared papers, 2024–2026 · strength 0.72
  7. Boris Pasche · 4 shared papers, 2024–2026 · strength 0.72
  8. Husain Yar Khan · 4 shared papers, 2024–2026 · strength 0.72
  9. Amro Aboukameel · 4 shared papers, 2024–2026 · strength 0.72
  10. Ramzi M. Mohammad · 4 shared papers, 2024–2026 · strength 0.72
  11. Bassel F. El‐Rayes · 4 shared papers, 2024–2026 · strength 0.72
  12. Rajvi Patel · 4 shared papers, 2019–2020 · strength 0.61
  13. Jessy Warner‐Cohen · 3 shared papers, 2020 · strength 0.55
  14. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
  15. Eliza Wright Beal · 3 shared papers, 2024–2026 · strength 0.54
  16. Alexios S Strimpakos · 10 shared papers, 2011–2013 · strength 0.52
  17. Irfana Muqbil · 1 shared paper, 2026 · strength 0.50
  18. Kristin Kaley · 8 shared papers, 2011–2016 · strength 0.48
  19. Jeffrey Chi · 3 shared papers, 2020–2021 · strength 0.47
  20. Martin D. Goodman · 5 shared papers, 2012–2020 · strength 0.42
  21. Frank Charles Passero · 4 shared papers, 2015–2017 · strength 0.40
  22. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  23. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
  24. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  25. Maged Mofied Ghaly · 2 shared papers, 2019–2021 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.